Mon panier

VEGF-C

VEGF-C Informations sur la molécule

Nom anglaisVascular endothelial growth factor CNombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleLMPHM4,Vascular Endothelial Growth Factor-Related Protein,Flt4-L,VRP,FLT4 Ligand DHM,LMPH1D,VEGF-C,Vascular Endothelial Growth Factor C,Flt4 ligand,VEGFC
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisVascular endothelial growth factor C
Alias de la cibleLMPHM4,Vascular Endothelial Growth Factor-Related Protein,Flt4-L,VRP,FLT4 Ligand DHM,LMPH1D,VEGF-C,Vascular Endothelial Growth Factor C,Flt4 ligand,VEGFC
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

VEGF-C Liste de produits

  • Attribut

    Protein (3)

  • Bibliothèque de produits

    En ligne (3)

  • Espèces

    Human (1)Cynomolgus (1)Mouse (1)

  • Étiquette

    His Tag (1)His Tag & Avi Tag (2)

  • Marqueur

    Unconjugated (1)Biotin-labeled (2)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
VEC-H52H3
Human
HEK293
Human VEGF-C / Flt4-L Protein, His Tag, low endotoxin (MALS verified)
Ajouter au panier
VEC-M82E3
Mouse
HEK293
Biotinylated Mouse VEGF-C Protein, His,Avitag™ (MALS verified)
Ajouter au panier
VEC-C82E4
Cynomolgus
HEK293
Biotinylated Cynomolgus VEGF-C Protein, His,Avitag™ (MALS verified)
Ajouter au panier
Quantité totale3
  • 1

VEGF-CContexte de la molécule

Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

VEGF-CAlias de la molécule

VEGFC,Flt4-L,VRP

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
VEGF-C gene therapy (Herantis Pharma)LX-1101; Ad-VEGF-CPhase 2 ClinicalHerantis PharmaLymphedema
Details
IBI-333IBI-333Phase 1 ClinicalMacular Degeneration; Wet Macular Degeneration
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques